CIC
ATRS

Cornercap Investment Counsel’s Antares Pharma, Inc. ATRS Stock Holding History

Cornercap Investment Counsel’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-138,771
Closed -$495K – 661
2021
Q4 		$495K Buy
+138,771
New +$485K 0.07% 460

Other funds holding ATRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Amundi
Amundi Paris, France $367B AUM 31.23% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Cornercap Investment Counsel's ATRS Position: Q1 2022 in Review

Cornercap Investment Counsel sold out of Antares Pharma, Inc. (ATRS) in Q1 2022, closing a stake of 138,771 shares — an estimated $495K sold.

Cornercap Investment Counsel first reported a position in ATRS in Q4 2021 and held it in 1 quarter. The position peaked at $495K in Q4 2021. 177 funds tracked by Wall St. Rank hold ATRS as of Q1 2022.

  • Cornercap Investment Counsel reported no remaining Antares Pharma, Inc. position as of Q1 2022 after selling out during the quarter.
  • Cornercap Investment Counsel sold 138,771 Antares Pharma, Inc. shares in Q1 2022, an estimated $495K.
  • Cornercap Investment Counsel first reported a position in Antares Pharma, Inc. in Q4 2021 and held it in 1 quarter.
  • Cornercap Investment Counsel's Antares Pharma, Inc. position peaked at $495K in Q4 2021.
  • 177 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q1 2022.

Based on Cornercap Investment Counsel's 13F filing for Q1 2022, filed 10 May 2022.